Global Oncology Based In-Vivo CRO Market 2024 : SWOT Analysis Of Key Driving Factors For Growing CAGR Value | Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Oncology Based In-Vivo CRO Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $2 billion In 2028 At A CAGR Of 9.7% :

The oncology based in-vivo cro market size has grown strongly in recent years. It will grow from $1.27 billion in 2023 to $1.38 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing focus on oncology therapeutics, increasing incidence of cancer, shift towards personalized medicine, pharmaceutical industry growth, demand for target-specific therapies.

The oncology based in-vivo cro market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging market opportunities, shift towards immuno-oncology therapies, rise in oncology clinical trials, precision medicine and targeted therapies. Major trends in the forecast period include regenerative medicine and cell therapies, demand for faster drug development, digitalization and data analytics, focus on tumor microenvironment, rise in biologics and immunotherapies.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Oncology Based In-Vivo CRO Market Major Segments
The oncology based in-vivo cro market covered in this report is segmented -

1) By Indication: Blood Cancer, Solid Tumors, Other Indications
2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models
3) By Application: Hospitals, Rehabilitation Centers

Key Driver - Surging Cancer Prevalence Fuels Growth In The Oncology-Based In-Vivo Cro Market

The growing prevalence of cancer is expected to propel the growth of the oncology-based in-vivo CRO market going forward. Cancer refers to a group of diseases in which abnormal cells divide uncontrollably, go beyond their usual boundaries, originate in almost any organ or tissue of the body, and spread through the blood and lymph systems to other parts of the body. Treatment and diagnosis of cancer require innovative drugs and devices, which undergo different preclinical trials, clinical trials, and regulatory processes before they enter the market. An oncology in-vivo-based CRO is a company hired by a sponsor company that provides research services such as performing complete or partial steps of running a preclinical in-vivo study (testing or with living organisms such as animals, plants, or whole cells) before the drug or device is trialed in humans. With the increasing prevalence of cancer, the demand for innovative treatments and therapies has also increased, driving the growth of the oncology-based in-vivo CRO market. For instance, in 2021, according to the journal published by the American Chemical Society (ACS), a US-based non-profit organization that supports scientific inquiry in the field of chemistry, the global burden of cancer is expected to be 28.4 million cases in 2040, a 47% rise from 2020. The growing prevalence of cancer is driving the oncology-based in-vivo CRO market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=10521&type=smp

Prominent Trend - Innovations In Oncology-Based In-Vivo Cros With 3D Ex Vivo Patient Tissue Platform

Major companies operating in the oncology-based in vivo CRO market are focused on developing new solutions to sustain their position in the market. In October 2021, Crown Bioscience, a CRO that provides discovery, preclinical, and translational platforms and services, launched the 3D Ex Vivo Patient Tissue Platform for improving response predictability to immuno-oncology drug candidates. The platform combines phenotypic three-dimensional models of fresh patient tumors with high-content imaging analysis, providing relevant analysis of drug responses that enables candidate selection and clinical program design. Patient tumor tissue isolated from biopsies, ascites, surgical resections, or pleural effusion samples that are processed within 24 hours is utilized by the platform to preserve the tumor microenvironment. High-content 3D imaging and image analysis are used by automated high-throughput platforms to quantify the distinct responses of individual cell populations in fresh patient tissues. Combined results and analysis determine the effects of the drug or combination of drugs on immune cell proliferation and tumor killing.

Oncology Based In-Vivo CRO Market Players
Major companies operating in the oncology based in-vivo cro market report are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Clintec International Private Limited, Worldwide Clinical Trials Inc., Pharm-Olam LLC, Clinipace Clinical Research Private Limited, Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, GenScript Biotech Corporation, Shanghai Medicilon Inc., Oncolys BioPharma Inc., Pharmalegacy Laboratories, Oncotest GmbH, Oncovision, Biocytogen LLC, Innovent Biologics Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the oncology based in-vivo CRO market in 2023. North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Oncology Based In-Vivo CRO Market Report Structure
3. Oncology Based In-Vivo CRO Market Trends And Strategies
4. Oncology Based In-Vivo CRO Market - Macro Economic Scenario
5. Oncology Based In-Vivo CRO Market Size And Growth
…..
27. Oncology Based In-Vivo CRO Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.